Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 410

Sort by

Sort Order Select

Journal Articles

Class I PI3K Is Required for HSC Differentiation

Kristina Ames, PhD, Imit Kaur, PhD, Meng Tong, Shayda Hemmati, PhD, Ellen Tein, Shira Glushakow-Smith, Lindsay Gurska, Kira Gritsman, MD PhD

Blood (2019) 134 (Supplement_1): 2461.

https://doi.org/10.1182/blood-2019-123823

Published: 2019

Journal Articles

Whole-Genome CRISPR Screen Reveals the Mechanism of Relapse in Patient-Derived Cells Representing High-Risk Paediatric ALL

Katarzyna Szoltysek, PhD, Helen Blair, Sirintra Nakjang, Ricky Tirtakusuma, Mankaran Singh, Ryan Nelson, Hesta McNeill, Catherine Dodd, Melanie Beckett, Lynsey McKenzie, Edward Law, Josef Vormoor, MD PhD, Deepali Pal, Olaf Heidenreich

Blood (2019) 134 (Supplement_1): 3952.

https://doi.org/10.1182/blood-2019-124818

Published: 2019

Journal Articles

Role of Autophagy in Resistance of FLT3-ITD AML Stem Cells to FLT3 TKI Treatment

Shaowei Qiu, MD, Chengcheng Yan, MD, Andrew J Paterson, PhD, Hui Li, BS, Nick Anderson, BS, Ajay Abraham, PhD, Jianbo He, MD, Mansi Shah, PhD, Puneet Agarwal, Jing Yang, PhD, Min Xie, MD, Rui Lu, PhD, Rob S. Welner, PhD, Ravi Bhatia, MD

Blood (2019) 134 (Supplement_1): 2548.

https://doi.org/10.1182/blood-2019-124948

Published: 2019

Journal Articles

CK2 Inhibitor CX4945 Shows Strong In Vivo Synergistic Anti-Leukemia Activity with Rapamycin in B-ALL Due to Enhanced Ikaros Mediated Repression of mTOR Pathway

Chandrika Gowda, MBBS, Chunhua Song, MD, Yali Ding, PhD, Pavan kumar Dhanyamraju, PhD, Soumya Iyer, PhD, Jonathon Payne, Yevgeniya Bamme, MD, Arati Sharma, PhD, Kimberly J. Payne, PhD, Sinisa Dovat, MD PhD

Blood (2019) 134 (Supplement_1): 2634.

https://doi.org/10.1182/blood-2019-131790

Published: 2019

Journal Articles

Associations between Microrna Expression, Disease Progression and Ex Vivo Drug Response in Multiple Myeloma

Romika Kumari, PhD, Ashwini Kumar, MRes, Alun Parsons, Minna Suvela, MSC, Juha Lievonen, MD, Raija Helena Silvennoinen, MD PhD, Pekka Anttila, MD, Caroline A Heckman, PhD

Blood (2019) 134 (Supplement_1): 3069.

https://doi.org/10.1182/blood-2019-128181

Published: 2019

Journal Articles

Inhibition of PIM Kinases Targets Synthetic Vulnerabilities and Enhances Antigen Presentation in B-Cell Lymphoma

Patrizia Mondello, MD PhD MSc, Chiara Tarantelli, PhD, Luciano Cascione, PhD, Alberto Arribas, PhD, Andrea Rinaldi, Anas Younes, MD, Francesco Bertoni, MD

Blood (2019) 134 (Supplement_1): 2858.

https://doi.org/10.1182/blood-2019-125123

Published: 2019

Journal Articles

Study Design of an Open-Label, Single-Arm, Multicenter, Phase 2 Study to Evaluate the Safety and Efficacy of Defibrotide in Adult Patients with Transplant-Associated Thrombotic Microangiopathy

Vincent T. Ho, Nino Keshelava, Suzanne Swann, William Tappe

Blood (2019) 134 (Supplement_1): 3257.

https://doi.org/10.1182/blood-2019-123520

Published: 2019

Journal Articles

Acquired Dysfibrinogenemia Krakow III after Everolimus Therapy

Alona A. Merkulova, MA, Steven C. Mitchell, MA, Sergei Merkulov, PhD, Alisa S. Wolberg, PhD, Neerman-Arbez Marguerite, PhD, Alvin H. Schmaier, MD

Blood (2019) 134 (Supplement_1): 4934.

https://doi.org/10.1182/blood-2019-131319

Published: 2019

Journal Articles

mTOR Signal Pathway Inhibition Promote the Cytotoxicity of Chemotherapy on SHI-1 Cells

Jing Xu, Zhenjiang Li, Jifu Zheng, Qiong Wu, Qingming Wang, Aiping Tang, Yuan Song, Yan Fei

Blood (2019) 134 (Supplement_1): 5126.

https://doi.org/10.1182/blood-2019-126714

Published: 2019

Journal Articles

Mutant ASXL1 Promotes Expansion of the Phenotypic Hematopoietic Stem Cell Compartment

Takeshi Fujino, MD, Susumu Goyama, MD PhD, Yuki Sugiura, PhD, Daichi Inoue, MD PhD, Satoshi Yamasaki, PhD, Akiko Matsumoto, Naru Sato, MD, Hironobu Morinaga, PhD, Shiori Shikata, Tomofusa Fukuyama, MD PhD, Yosuke Tanaka, PhD, Shuhei Asada, MD PhD, Tsuyoshi Fukushima, MD PhD, Hiroaki Honda, MD PhD, Emi K Nishimura, MD PhD, Tatsuhiro Shibata, MD PhD, Makoto Suematsu, MD PhD, Toshio Kitamura, MD PhD

Blood (2019) 134 (Supplement_1): 821.

https://doi.org/10.1182/blood-2019-127904

Published: 2019

Journal Articles

Deletion of CISH in Human Pluripotent Stem Cell-Derived Natural Killer Cells Enhances Anti-Tumor Activity Via Metabolic Reprogramming

Huang Zhu, PhD, Robert Blum, Zhengming Wu, Zhipeng Meng, PhD, Kun-Liang Guan, PhD, Dan S Kaufman, MD PhD

Blood (2019) 134 (Supplement_1): 619.

https://doi.org/10.1182/blood-2019-124446

Published: 2019

Journal Articles

Quantitative Investigation of Pharmacologically Modulated Signaling and Efficacy in ABC DLBCL Using a Systems Pharmacology Model

Kosinsky Yuri, PhD, Lulu Chu, PhD, Millie Shah, PhD, Karthick Vishwanathan, PhD, Connie Larsson, PhD, Andrew Bloecher, PhD, Brandon Willis, PhD, Hannah Dry, BSc, Kirill Peskov, PhD, Joseph Ware, PhD, Andrew Mortlock, PhD, Gabriel Helmlinger, PhD

Blood (2019) 134 (Supplement_1): 5304.

https://doi.org/10.1182/blood-2019-130879

Published: 2019

Journal Articles

Stearoyl-CoA Desaturase (SCD) Enhances Central Nervous System Leukemia

Angela Maria Savino, PhD, Orianne Olivares, PhD, Shani Barel, Lev Yakimov, Ifat Geron, Hila Fishman, Inbal Mor, Ifat Abramovich, Sara Isabel Fernandes, Eyal Gottlieb, Christina Halsey, MD PhD, Shai Izraeli, MD

Blood (2018) 132 (Supplement 1): 389.

https://doi.org/10.1182/blood-2018-99-114749

Published: 2018

Journal Articles

Alox15b Gene Contributes to Lymphoma Tumorigenesis Via PI3K/AKT/mTOR Pathway Activation and Has a Synergistic Effect with Alox5 Gene

Pengpeng Liu, MD, Yu Liu, PhD, Chong Chen, PhD, Ting Liu, MD, Ting Niu, MD PhD

Blood (2018) 132 (Supplement 1): 4112.

https://doi.org/10.1182/blood-2018-99-120130

Published: 2018

Journal Articles

Phase 2 Trial of Single Agent Gedatolisib (PF-05212384), a Dual PI3K/mTOR Inhibitor, for Adverse Prognosis and Relapse/Refractory AML: Clinical and Transcriptomic Results

Jacques Vargaftig, MD PhD, Hassan Farhat, MD, Lionel Ades, MD PhD, Adrien Briaux, Camille Benoist, Isabelle Turbiez, Norbert Vey, MD PhD, Sylvie Glaisner, MD, Céline Callens, PharmD, PhD

Blood (2018) 132 (Supplement 1): 5233.

https://doi.org/10.1182/blood-2018-99-117485

Published: 2018

Journal Articles

GSK458 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in T Cell Lymphomas As a Single Agent and in Combination Therapy

Juan Gu, MD PhD, Lianjuan Yang, MD PhD, Dennis C Gaughan, Ling He, MD PhD, Weina Shen, MD, Cory Mavis, BSc, MSc, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2018) 132 (Supplement 1): 5378.

https://doi.org/10.1182/blood-2018-99-113997

Published: 2018

Journal Articles

Targeting Autophagy as a Therapeutic Pathway in Diamond-Blackfan Anemia

Sergei Doulatov, PhD

Blood (2018) 132 (Supplement 1): SCI-28.

https://doi.org/10.1182/blood-2018-99-109478

Published: 2018

Journal Articles

Pre-Transplant Genetic Susceptibility in Adult Allogeneic Hematopoietic Cell Transplant Recipients: Incidence and Clinical Relevance in Transplant-Associated Thrombotic Microangiopathy

Blood (2018) 132 (Supplement 1): 3401.

https://doi.org/10.1182/blood-2018-99-112041

Published: 2018

Journal Articles

Omipalisib (GSK458), a Dual an-PI3K/mTOR Inhibitor, Exhibits in Vitro and In Vivo activity in Chemotherapy-Sensitive and -Resistant Models of Burkitt Lymphoma

Thomas Ippolito, MSc, Cory Mavis, BSc, MSc, Juan Gu, MD PhD, Francisco J. Hernandez-Ilizaliturri, MD, Matthew J. Barth, MD

Blood (2018) 132 (Supplement 1): 2951.

https://doi.org/10.1182/blood-2018-99-119048

Published: 2018

Journal Articles

Management of Cytopenias in CTLA4 Haploinsufficiency Using Abatacept and Sirolimus

Gulbu Uzel, MD, Djuro Karanovic, MD, Hua Su, PhD, Amy Rump, Anahita Agharahimi, Steven M. Holland, MD, V. Koneti Rao, MD FRCPA

Blood (2018) 132 (Supplement 1): 2409.

https://doi.org/10.1182/blood-2018-99-120185

Published: 2018

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Class I PI3K Is Required for HSC Differentiation

Whole-Genome CRISPR Screen Reveals the Mechanism of Relapse in Patient-Derived Cells Representing High-Risk Paediatric ALL

Role of Autophagy in Resistance of FLT3-ITD AML Stem Cells to FLT3 TKI Treatment

CK2 Inhibitor CX4945 Shows Strong In Vivo Synergistic Anti-Leukemia Activity with Rapamycin in B-ALL Due to Enhanced Ikaros Mediated Repression of mTOR Pathway

Associations between Microrna Expression, Disease Progression and Ex Vivo Drug Response in Multiple Myeloma

Inhibition of PIM Kinases Targets Synthetic Vulnerabilities and Enhances Antigen Presentation in B-Cell Lymphoma

Study Design of an Open-Label, Single-Arm, Multicenter, Phase 2 Study to Evaluate the Safety and Efficacy of Defibrotide in Adult Patients with Transplant-Associated Thrombotic Microangiopathy

Acquired Dysfibrinogenemia Krakow III after Everolimus Therapy

mTOR Signal Pathway Inhibition Promote the Cytotoxicity of Chemotherapy on SHI-1 Cells

Mutant ASXL1 Promotes Expansion of the Phenotypic Hematopoietic Stem Cell Compartment

Deletion of CISH in Human Pluripotent Stem Cell-Derived Natural Killer Cells Enhances Anti-Tumor Activity Via Metabolic Reprogramming

Quantitative Investigation of Pharmacologically Modulated Signaling and Efficacy in ABC DLBCL Using a Systems Pharmacology Model

Stearoyl-CoA Desaturase (SCD) Enhances Central Nervous System Leukemia

Alox15b Gene Contributes to Lymphoma Tumorigenesis Via PI3K/AKT/mTOR Pathway Activation and Has a Synergistic Effect with Alox5 Gene

Phase 2 Trial of Single Agent Gedatolisib (PF-05212384), a Dual PI3K/mTOR Inhibitor, for Adverse Prognosis and Relapse/Refractory AML: Clinical and Transcriptomic Results

GSK458 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in T Cell Lymphomas As a Single Agent and in Combination Therapy

Targeting Autophagy as a Therapeutic Pathway in Diamond-Blackfan Anemia

Pre-Transplant Genetic Susceptibility in Adult Allogeneic Hematopoietic Cell Transplant Recipients: Incidence and Clinical Relevance in Transplant-Associated Thrombotic Microangiopathy

Omipalisib (GSK458), a Dual an-PI3K/mTOR Inhibitor, Exhibits in Vitro and In Vivo activity in Chemotherapy-Sensitive and -Resistant Models of Burkitt Lymphoma

Management of Cytopenias in CTLA4 Haploinsufficiency Using Abatacept and Sirolimus

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only